MACROGENICS INC (MGNX): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 17:28 ET
- Event date
- 2026-11-13
- Accession no.
- 0001125345-26-000077
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
MacroGenics updates clinical program details and cash runway guidance in presentation
MacroGenics made an updated corporate presentation available on November 13, 2026, with clinical program details. It reported a 27.3% best overall response rate in MGC026's SCCHN expansion cohort, based on preliminary data at September 1, 2026. The presentation also reported $288M in cash equivalents and marketable securities and cash runway guidance through 2028.
- MGC026's SCCHN expansion cohort had a best overall response rate of 6/22 (27.3%) at the September 1, 2026 data cutoff.
- The cohort's confirmed objective response rate was 4/22 (18.2%); data are not final and subject to change.
- Cash equivalents and marketable securities were $288M as of September 30, 2026.
- The presentation included cash runway guidance through 2028.
productguidance
Items reported
- Item 7.01: Regulation FD Disclosure
The company is making information public under Regulation FD, which requires broad public disclosure of material information shared with certain market participants. Investor presentations and press releases are common. Like Item 2.02, this information is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | mgnx-20261113.htm |
| EX-99.1 | EX-99.1 | macrogenicscorporateover.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.